AI-Driven Drug Safety and Pharmacovigilance Platforms Market Report 2026: Targeting 20.2% CAGR with Microsoft, IBM, Oracle, IQVIA, and Veeva
Yahoo Finance ·
The global market for artificial intelligence-driven drug safety and pharmacovigilance platforms is experiencing robust expansion, projected to climb from $2.14 billion in 2025 to $2.59 billion in 2026 at a compound annual growth rate of 20.6%. Looking further ahead, the sector is anticipated to reach $5.39 billion by 2030, maintaining a steady compound annual growth rate of 20.2%. Key catalysts driving this trajectory include the integration of artificial intelligence into safety surveillance architectures, expanding utilization of real-world evidence, and heightened regulatory demands for automated compliance reporting. Industry participants are increasingly capitalizing on cloud integration, predictive analytics, and automated case processing to minimize manual workloads and optimize signal detection. Illustrating the escalating volume of data, the Department of Health Abu Dhabi reported 1,522 adverse drug reaction submissions in 2023, marking a 235% surge from historical annual averages. Major technology providers such as Microsoft, IBM, Oracle, IQVIA, and Veeva continue to shape this evolving landscape.
AI 시장 분석
The AI-based drug safety and pharmacovigilance platform market is projected to grow at a CAGR of 20.2%, from $2.59 billion in 2026 to $5.39 billion in 2030. According to a Department of Health Abu Dhabi report, adverse event reports have surged by 235% compared to past averages, driving demand for automation technologies. Investors should focus on the profitability of cloud and AI automation segments from major tech companies such as Microsoft, IBM, and Oracle.
상승 영향
- AI — The drug safety and pharmacovigilance platform market is recording a high CAGR of 20.2%, acting as a direct tailwind for the related revenue and profitability of AI technology providers such as Microsoft, IBM, and Oracle.
- Biotech — As the regulatory environment tightens with a 235% surge in adverse event reports, pharmaceutical and healthcare companies are increasing their adoption of automated AI safety monitoring systems, yielding clinical efficiency and regulatory compliance cost savings.
DYAX 전담 분석
The 20.2% CAGR in the AI-based pharmacovigilance platform market reflects infrastructure demand that reduces manual workloads for pharmaceutical companies and maximizes regulatory compliance efficiency. With adverse event reports surging 235% year-over-year, this directly translates to revenue expansion for big tech and healthcare IT firms possessing natural language processing and predictive analytics technologies.
The bullish scenario involves accelerated adoption of related platforms driven by regulatory mandates for automated reporting, while the bearish scenario is a slowdown in adoption speed due to stringent AI regulations and data security issues. Key monitoring metrics are the healthcare segment revenue growth rates of major tech firms and the number of AI platform adoption contracts by pharmaceutical companies.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 43% · Bearish (Short) 57%
468 participants
Related News
- Western Digital, Allegro MicroSystems, Amtech, and Teradyne Shares Surge on Major Tech Financing
- Cerebras Systems Stock Surges on Major Tech Collaboration
- Apple Prepares Touch MacBooks Debut as Baker Hughes and NXP Report Strong Quarterly Results
- SK Enmove Overcomes Middle East Crisis, Driven by Global No. 1 Lube Base Oil
- CoreWeave Stock Climbs 6% Despite Lingering Investor Anxiety
- Hana Tour Partners with Salesforce Korea to Boost Corporate Travel
